NEURALSTEM ANNOUNCES PUBLICATION OF LONG TERM CELL SURVIVAL FROM PHASE I NSI-566 ALS STUDY IN THE JOURNAL "ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY" Study Concludes NSI-566 Cells Survived for up to 2.5 Years After
Monday, November 10, 2014 BiopharmaWatch Research 1 min read
Key Takeaway: NEURALSTEM ANNOUNCES PUBLICATION OF LONG
TERM CELL SURVIVAL FROM PHASE I NSI-566 ALS STUDY IN THE JOURNAL "ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY"
Study Concludes NSI-566 Cells Survived
for up to 2.5 Years After Transplantation
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+50%
120-day peak, hindsight
Typical move
6.1%
average across 7 past catalysts
Cash runway
~49 mo
Minimal dilution risk
Lead asset
PALI-2108
Phase 1 · Fibrostenotic Crohn's Disease
Full Press Release Details
NEURALSTEM ANNOUNCES PUBLICATION OF LONG
TERM CELL SURVIVAL FROM PHASE I NSI-566 ALS STUDY IN THE JOURNAL "ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY"